<DOC>
	<DOCNO>NCT00228436</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacodynamics ( PD ) , pharmacokinetics ( PK ) multiple subcutaneous injection peginesatide participant chronic kidney disease ( CKD ) dialysis receive erythropoiesis stimulate agent ( ESA ) treatment .</brief_summary>
	<brief_title>Safety , PD &amp; PK Multiple Doses Peginesatide Anemia Chronic Kidney Disease Patients</brief_title>
	<detailed_description>This Phase 2 , dose find study design evaluate peginesatide treatment participant CKD ESA treatment . The objective determine range dose peginesatide administer subcutaneously every 4 week ( Q4W ) increase maintain hemoglobin 11 13 g/dL .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Participant inform investigational nature study give write , witness informed consent accordance institutional , local national guideline ; Males females ≥ 18 ≤ 85 year age . Premenopausal female ( exception surgically sterile ) must negative pregnancy test screening ; sexually active must practice adequate form contraception least 4 week prior study start , must willing continue contraception least 4 week last dose study drug ; Chronic kidney disease stage 3 4 ( estimate Glomerular filtration rate [ GFR ] 1560 mL/min within 28 day prior study drug administration ) expect begin dialysis least 12 week ; Two hemoglobin value ≥ 9.0 &lt; 11.0 g/dL within 14 day prior study drug administration , include least one value draw within 7 day prior study drug administration ; One serum ferritin level ≥ 100 microgram per liter ( μg/L ) transferrin saturation ≥ 20 % within 4 week prior study drug administration ; One serum red cell folate level low limit normal within 4 week prior study drug administration ; One vitamin B12 level lower limit normal within 4 week prior study drug administration ; Weight ≥ 45 kg within 4 week prior study drug administration ; One white blood cell count ≥ 3.0 x 10^9/L within 4 week prior study drug administration ; One platelet count ≥ 100 x 10^9/L within 4 week prior study drug administration . Prior treatment erythropoiesis stimulate agent 12 week prior study drug administration ; Any prior treatment Eprex® ; Known intolerance erythropoiesis stimulate agent ; History antibodies erythropoiesis stimulate agent history pure red cell aplasia ; Prior hemodialysis peritoneal dialysis treatment ; Known intolerance parenteral iron supplementation ; Red blood cell transfusion within 12 week prior study drug administration ; Hemoglobinopathy [ e.g. , homozygous sicklecell disease ( sicklecell trait exclude patient ) , thalassemia type , etc . ] ; Known hemolysis ; Chronic , uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) ; C Reactive Protein ( CRP ) great 30 mg/L within 4 week prior study drug administration ; Febrile illness within 7 day prior study drug administration ; Uncontrolled symptomatic secondary hyperparathyroidism ; Poorly control hypertension within 4 week prior study drug administration , per Investigator 's clinical judgment ( e.g . systolic ≥ 170mm Hg , diastolic ≥ 100 mm Hg repeat reading ) ; Epileptic seizure 6 month prior study drug administration ; Chronic congestive heart failure ( New York Heart Association Class IV ) ; High likelihood early withdrawal interruption study ; Evidence malignancy within past 5 year ( except nonmelanoma skin cancer exclusion criterion ) ; Life expectancy &lt; 12 month ; Anticipated elective surgery study period ; Previous exposure investigational agent within 6 week prior administration study drug plan receipt study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>